De Novo Design of Bipartite Mini-Protein IgE/FcεRI Interaction Inhibitors for Allergic Disease Treatment

IgE-FcεRI interaction plays a central role in the pathogenesis of allergic diseases. Nevertheless, existing anti-IgE antibodies (such as Omalizumab) cannot disrupt the preformed IgE-FcεRI complex at therapeutic concentrations. Here we present a de novo design strategy for bipartite mini-protein inhibitors of the IgE-FcεRI interaction that engage both the Site 1 and Site 2 interfaces of FcεRIα on a single chain, joined by a flexible (GGGGS)n linker. Using the BindCraft framework, we designed Site 1 and Site 2 minibinders and measured their monovalent affinities by surface plasmon resonance (SPR); three Site 1 binders (KD = 3.90, 7.27, and 9.76 nM, respectively) and one Site 2 binder (KD = 2.25 nM) were selected for fusion. A seven-stage computational pipeline determined the fusion orientation, set the linker length, built, sampled, and geometrically validated clash-free (GGGGS)n linkers, resulting in three atomic models for the three Site 1 binder-(GGGGS)n-Site 2 binder fusions. Avidity was predicted with the effective molarity (EM) model that combines the Crothers–Metzger bivalent relation with a worm-like-chain end-density for the effective concentration, showing that the three fusions are predicted to bind FcεRIα with sub-picomolar effective dissociation constants (0.017, 0.009, and 0.003 pM), binding 2.8×10³–1.5×10⁴-fold tighter to FcεRI than IgE itself (KD = 48.4 pM). These predictions suggest that bipartite mini-protein blockers could rival and potentially displace IgE at FcεRIα, offering a mechanistically distinct alternative to current anti-IgE therapies, although experimental validation of the predicted avidity remains to be performed.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-17
DOI
https://doi.org/10.20944/preprints202611.1625.v1
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

De Novo Design of Bipartite Mini-Protein IgE/FcεRI Interaction Inhibitors for Allergic Disease Treatment

Yeping Sun
2 links
Preprints.org
Monoclonal and Polyclonal Antibodies Research
preprint

De Novo Design of Bipartite Mini-Protein IgE/FcεRI Interaction Inhibitors for Allergic Disease Treatment

Yeping Sun
preprint en

Abstract

IgE-FcεRI interaction plays a central role in the pathogenesis of allergic diseases. Nevertheless, existing anti-IgE antibodies (such as Omalizumab) cannot disrupt the preformed IgE-FcεRI complex at therapeutic concentrations. Here we present a de novo design strategy for bipartite mini-protein inhibitors of the IgE-FcεRI interaction that engage both the Site 1 and Site 2 interfaces of FcεRIα on a single chain, joined by a flexible (GGGGS)n linker. Using the BindCraft framework, we designed Site 1 and Site 2 minibinders and measured their monovalent affinities by surface plasmon resonance (SPR); three Site 1 binders (KD = 3.90, 7.27, and 9.76 nM, respectively) and one Site 2 binder (KD = 2.25 nM) were selected for fusion. A seven-stage computational pipeline determined the fusion orientation, set the linker length, built, sampled, and geometrically validated clash-free (GGGGS)n linkers, resulting in three atomic models for the three Site 1 binder-(GGGGS)n-Site 2 binder fusions. Avidity was predicted with the effective molarity (EM) model that combines the Crothers–Metzger bivalent relation with a worm-like-chain end-density for the effective concentration, showing that the three fusions are predicted to bind FcεRIα with sub-picomolar effective dissociation constants (0.017, 0.009, and 0.003 pM), binding 2.8×10³–1.5×10⁴-fold tighter to FcεRI than IgE itself (KD = 48.4 pM). These predictions suggest that bipartite mini-protein blockers could rival and potentially displace IgE at FcεRIα, offering a mechanistically distinct alternative to current anti-IgE therapies, although experimental validation of the predicted avidity remains to be performed.

Preprints.org
Good health and well-being
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon